#United States #New York #Class Action #Pomerantz Law Firm #Unicycive Therapeutics

Pomerantz Law Firm Investigates Unicycive Therapeutics

In a significant development within the pharmaceutical industry, Pomerantz LLP is currently looking into potential claims on behalf of investors of Unicycive Therapeutics, Inc. This investigation follows alarming news affecting the company's stock and ongoing scrutiny regarding its business practices.

Background of Unicycive Therapeutics

Unicycive Therapeutics, listed on NASDAQ under the ticker UNCY, focuses on developing therapies for chronic kidney disease (CKD). Recently, the company experienced a considerable drop in its stock price after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) pertaining to its New Drug Application (NDA) for a product meant to treat hyperphosphatemia in CKD patients undergoing dialysis. This letter cast doubt on the efficacy and safety of their application and subsequently affected investor confidence.

The Investigation

The Pomerantz Law Firm is investigating whether Unicycive Therapeutics and its executives may have participated in securities fraud or other illegal activities. Legal experts urge investors who may have suffered losses related to their investment in Unicycive to reach out for further assistance. This inquiry is crucial as it seeks to determine if the company misled investors regarding its FDA application and operational integrity. Investors who wish to join a class action can contact the firm directly.

Financial Implications

On June 30, 2025, following the FDA's communication, Unicycive’s stock plummeted by $2.03, a staggering drop of about 29.85%, ultimately closing at $4.77 per share. Such a decline illustrates the profound impact regulatory decisions can have on a company's market value and investor sentiment.

About Pomerantz LLP

Founded over 85 years ago by a pioneer in class action litigations, Pomerantz LLP is recognized as one of the leading law firms specializing in corporate, securities, and antitrust class actions. With a global presence, including offices in New York, Chicago, and several international cities, Pomerantz has a strong history of recovering significant financial compensations for victims of corporate misconduct.

Conclusion

As the investigation unfolds, both current and potential investors in Unicycive Therapeutics must stay informed and consider their legal options. The situation exemplifies the volatility of the pharmaceutical industry and the critical nature of regulatory approvals. Interested parties are encouraged to follow this developing story and consult with legal professionals as necessary.

For any inquiries or to become involved in the investigation, investors may contact Danielle Peyton at Pomerantz LLP via email at [email protected] or by calling 646-581-9980 ext. 7980. This is an alert for those who wish to safeguard their investments amidst these trying circumstances.